Clover Health Investments Corp is a healthcare technology company... Show more
Clover Health's quarterly results have become a key gauge of whether its technology-led Medicare Advantage strategy can convert rapid membership growth into durable profitability. The company has spent recent years expanding enrollment while leaning on its Clover Assistant software platform to manage care and control medical costs. In the prior-year third quarter, higher utilization and a surge of new members pressured margins, sending shares lower. This latest report matters because investors are watching whether those newer member cohorts have matured into profitable contributors and whether Clover can sustain its above-market revenue growth without sacrificing the Insurance BER. The results also carry weight for the broader managed-care sector, which has been navigating elevated medical costs and evolving Medicare Advantage payment dynamics.
Clover Health delivered a top- and bottom-line beat for the third quarter of 2026. Total revenue rose 52.9% year over year to $759.3 million, ahead of the consensus estimate of roughly $740 million. GAAP net income came in at $6.4 million, or $0.01 per share, versus a net loss of $24.4 million, or $0.05 per share, in the same period a year ago. Analysts had modeled approximately breakeven earnings per share.
Adjusted EBITDA reached $16.05 million, comfortably exceeding the consensus of about $10 million and reflecting a 2.1% margin. Operating margin improved to 0.8%, up from negative 4.9% a year earlier, while free cash flow margin expanded to 9.2% from 2.3%. The turnaround was driven by strong enrollment and better cost management: period-end Medicare Advantage membership grew to 158,907, up 45% year over year, and the Insurance BER improved 240 basis points to 91.1%. Insurance segment gross profit climbed to $94.7 million from $50.3 million a year earlier.
Alongside the results, management raised the low end of its full-year 2026 outlook. The company now expects total revenue of $2.97 billion to $3.00 billion, GAAP net income of $25 million to $35 million, consolidated gross profit of $540 million to $555 million, and adjusted EBITDA of $75 million to $85 million.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking managed-care names like Clover Health, the AI Screener offers a structured way to compare peers and identify signals across the sector.
Initial market reaction to the report was muted, with shares holding near $4.67 in the immediate aftermath of the release. That relative stability stands in contrast to the prior-year quarter, when a profitability miss and higher cost guidance triggered a sharp sell-off. This time, the beat on revenue, earnings per share, and adjusted EBITDA, combined with a raised outlook, appeared to reassure investors that the company's growth is translating into operating leverage. Sentiment has been supported by Clover's progress toward its first full year of GAAP profitability, though investors remain attentive to whether medical cost trends stay contained as new members continue to join the platform.
Looking ahead, the most important variable is whether Clover can keep converting its large base of new members into profitable, returning cohorts. Management's updated 2026 guidance points to roughly $80 million in adjusted EBITDA at the midpoint and a first full year of GAAP net income profitability, but execution will depend on sustaining the improvement in the Insurance BER.
Investors should monitor medical cost trends, including utilization and pharmacy costs, which have historically been the biggest swing factor for Medicare Advantage margins. Any renewed pressure there could offset the benefits of rapid enrollment growth.
Membership momentum and 2027 open enrollment will also be closely watched, particularly as Clover competes for seniors in an environment where some larger rivals have pulled back. Retention, plan benefits, and star ratings remain important longer-term drivers of payment rates and growth capacity.
Finally, the expansion of Counterpart Health, the company's technology arm aimed at providers outside its own plans, offers a secondary catalyst worth tracking. Success there could broaden Clover's revenue base beyond its Medicare Advantage book, though it remains a smaller contributor to near-term results.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry ManagedHealthCare